Active Ingredient: IPRATROPIUM
(Hérité de IPRATROPIUM AGUETTANT ADULTES 0) Ipratropium bromide should be administered as first line therapy to all patients in an attempt to reduce the need for inhaled ß-agonists in infants with LQTS (https://doi.org/10.1016/j.prrv.2011.02.003) However a case-control study in ICU patients suggests that Ipratropium may be associated with QT interval prolongation. (https://doi.org/10.1371/journal.pone.0263117)
https://doi.org/10.1016/j.prrv.2011.02.003, https://doi.org/10.1016/j.anai.2018.07.027, https://www.cidg.org.nz/wp-content/uploads/2015/03/Medications-to-Avoid-in-Long-QT-Syndrome.pdf, https://doi.org/10.1371/journal.pone.0263117